Nevirapine
Side effects
Options:
Hide MedDRA Preferred Terms
MedDRA Preferred Term
|
Side effect
|
Data for drug
|
Placebo
|
Labels
|
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
16
|
Dermatitis
|
Rash
|
postmarketing — 4% - 24%
|
1.5% - 14.9%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Rash
|
Rash
|
postmarketing — 4% - 24%
|
1.5% - 14.9%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Liver function test abnormal
|
Liver function test abnormal
|
common, 1.2% - 6.7%
|
0.9% - 1.5%
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
Alanine aminotransferase increased
|
Alanine aminotransferase increased
|
common
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Headache
|
Headache
|
common, 0.7% - 4%
|
0.4% - 1%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Abdominal pain
|
Abdominal pain
|
common, 0.1% - 3%
|
0% - 1%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Gastrointestinal pain
|
Abdominal pain
|
common, 0.1% - 3%
|
0% - 1%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Diarrhoea
|
Diarrhoea
|
common, 0.2% - 4%
|
0.5% - 1%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Nausea
|
Nausea
|
common, 0.5% - 9%
|
1% - 4%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Hepatotoxicity
|
Hepatotoxicity
|
common, 2% - 2.4%
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
x
|
x
|
x
|
x
|
Myalgia
|
Myalgia
|
postmarketing — 0.2% - 1.2%
|
0% - 2%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
Musculoskeletal discomfort
|
Myalgia
|
postmarketing — 0.2% - 1.2%
|
0% - 2%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
Arthralgia
|
postmarketing — 2%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Drug eruption
|
Drug eruption
|
uncommon
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
x
|
Blood pressure increased
|
Blood pressure increased
|
uncommon
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Blood phosphorus decreased
|
Blood phosphorus decreased
|
uncommon
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Agranulocytosis
|
Agranulocytosis
|
postmarketing — 0.4% - 3.3%
|
0% - 3%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Asthenia
|
Fatigue
|
postmarketing — 0.2% - 5%
|
0.3% - 4%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Fatigue
|
Fatigue
|
postmarketing — 0.2% - 5%
|
0.3% - 4%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Toxic epidermal necrolysis
|
Toxic epidermal necrolysis
|
postmarketing, uncommon
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Erythema multiforme
|
Stevens-Johnson syndrome
|
postmarketing — 0.3%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Erythema multiforme
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
Stevens-Johnson syndrome
|
Stevens-Johnson syndrome
|
postmarketing — 0.3%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Anaphylactic shock
|
Anaphylactic shock
|
postmarketing — common
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Anaemia
|
Anaemia
|
postmarketing — 7% - 7.3%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Angioedema
|
Angioedema
|
postmarketing — common
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Arthralgia
|
Arthralgia
|
postmarketing — 2%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Blister
|
Blister
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
Dermatitis bullous
|
Blister
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
Bullous eruption
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
Conjunctivitis
|
Conjunctivitis
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
Oedema
|
Oedema
|
postmarketing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Eosinophilia
|
Eosinophilia
|
postmarketing, uncommon
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Body temperature increased
|
Body temperature increased
|
postmarketing — 1% - 2%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Hepatitis
|
Hepatitis
|
postmarketing — 1.2% - 4%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Hypersensitivity
|
Hypersensitivity
|
postmarketing, common
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Jaundice
|
Jaundice
|
postmarketing, uncommon
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Neutropenia
|
Neutropenia
|
postmarketing, 8.9% - 9%
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
Paraesthesia
|
Paraesthesia
|
postmarketing
|
|
x
|
x
|
x
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
Paraesthesia skin
|
postmarketing
|
|
|
|
|
|
x
|
|
|
|
|
|
|
|
|
|
|
|
Rhabdomyolysis
|
Rhabdomyolysis
|
postmarketing
|
|
x
|
x
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
|
|
|
Mouth ulceration
|
Ulcerative stomatitis
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
Urticaria
|
Urticaria
|
postmarketing, uncommon
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Vomiting
|
Vomiting
|
postmarketing, common
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Hepatic failure
|
Hepatic failure
|
postmarketing, rare
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Oral disorder
|
Oral lesion
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
Hepatitis cholestatic
|
Hepatitis cholestatic
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
Hepatic necrosis
|
Hepatic necrosis
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
Malaise
|
Malaise
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
Discomfort
|
Malaise
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
Feeling abnormal
|
Malaise
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
Ill-defined disorder
|
Malaise
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
Pain
|
Ache
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
Hepatitis fulminant
|
Hepatitis fulminant
|
rare
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
Lymphadenopathy
|
Lymphadenopathy
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Face oedema
|
Face oedema
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
|
|
Drug reaction with eosinophilia and systemic symptoms
|
Hypersensitive syndrome
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
Drug interaction
|
Drug interaction
|
postmarketing
|
|
x
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
|
|
|
|
Somnolence
|
Somnolence
|
postmarketing
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
Congenital anomaly
|
Congenital anomaly
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
Developmental delay
|
Congenital anomaly
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
Decreased appetite
|
Anorexia
|
|
|
x
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
Autoimmune disorder
|
Autoimmune disorder
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Bone disorder
|
Bone disorder
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
Connective tissue disorder
|
Connective tissue disorder
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
x
|
x
|
Dermatitis exfoliative
|
Dermatitis exfoliative
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
Erythema nodosum
|
Erythema nodosum
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
Gastrointestinal disorder
|
Gastrointestinal disorder
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Basedow's disease
|
Basedow's disease
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Hepatitis toxic
|
Hepatitis toxic
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
Hypercholesterolaemia
|
Hypercholesterolaemia
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Hyperglycaemia
|
Hyperglycaemia
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Hypertriglyceridaemia
|
Hypertriglyceridaemia
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Blood triglycerides increased
|
Hypertriglyceridaemia
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Breast enlargement
|
Hypertrophy of breast
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Immune system disorder
|
Immune system disorder
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Inflammation
|
Inflammation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Insulin resistance
|
Insulin resistance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Lipodystrophy acquired
|
Lipodystrophy
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Liver disorder
|
Liver disorder
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
Hepatocellular injury
|
Liver disorder
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
Foetor hepaticus
|
Liver disorder
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
Necrosis
|
Necrosis
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
Nervous system disorder
|
Nervous system disorder
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Opportunistic infection
|
Opportunistic infection
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Pancreatitis
|
Pancreatitis
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
x
|
x
|
Neuropathy peripheral
|
Neuropathy peripheral
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
x
|
x
|
Pruritus
|
Pruritus
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Renal failure
|
Renal failure
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Thrombocytopenia
|
Thrombocytopenia
|
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
x
|
x
|
Ulcer
|
Ulcer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
Erythema
|
Erythema
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
Gamma-glutamyltransferase increased
|
Gamma-glutamyltransferase increased
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Aspartate aminotransferase increased
|
Aspartate aminotransferase increased
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Liver injury
|
Liver injury
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
Traumatic liver injury
|
Liver injury
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
Skin disorder
|
Unspecified disorder of skin and subcutaneous tissue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Rash erythematous
|
Rash erythematous
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Hepatic enzyme increased
|
Hepatic enzyme increased
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Skin exfoliation
|
Skin exfoliation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
Vertical infection transmission
|
Vertical infection transmission
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
Hepatobiliary disease
|
Hepatobiliary disease
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Hepatitis acute
|
Hepatitis acute
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
Rash maculo-papular
|
Rash maculo-papular
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
Transaminases increased
|
Transaminases increased
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Lipohypertrophy
|
Buffalo hump
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Chronic hepatitis B
|
Chronic hepatitis B
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
Surgery
|
Surgical intervention
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Hyperlactacidaemia
|
Hyperlactacidaemia
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
Fat redistribution
|
Fat redistribution
|
|
|
|
x
|
x
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
Rash papular
|
Rash papular
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
Hypertransaminasaemia
|
Hypertransaminasaemia
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Indications
Information about indications was extracted from the indications and usage sections of the labels.
Side effects: | 41 |
Source: | FDA Structured Product Label |
---|
Side effects: | 42 |
Source: | FDA |
---|
Side effects: | 41 |
Source: | FDA |
---|
Side effects: | 42 |
Source: | FDA |
---|
Side effects: | 43 |
Source: | FDA Structured Product Label |
---|
Side effects: | 43 |
Source: | FDA Structured Product Label |
---|
Side effects: | 43 |
Source: | FDA Structured Product Label |
---|
Side effects: | 43 |
Source: | FDA Structured Product Label |
---|
Side effects: | 43 |
Source: | FDA Structured Product Label |
---|
Side effects: | 43 |
Source: | FDA |
---|
Side effects: | 47 |
Source: | FDA Structured Product Label |
---|
Side effects: | 54 |
Source: | Health Canada |
---|
Side effects: | 46 |
Source: | Medsafe |
---|
Side effects: | 58 |
Source: | medicines.org.au |
---|
Side effects: | 60 |
Source: | EMA |
---|
Side effects: | 61 |
Source: | EMA |
---|
Color scheme:
standard – alternative
|
|
100%
|
|
|
75%
|
|
|
50%
|
|
|
10%
|
|
|
frequent (1% to 100%)
|
|
|
infrequent (0.1% to 1%)
|
|
|
rare (<0.1%)
|
|
|
postmarketing
|
|
|
0%
|
|
|
no frequency information
|
|
|
not found on label
|